摘要
支气管哮喘的经典病理、生理学研究认为,引起哮喘的主要病理学改变主要是由于支气管的平滑肌发生痉挛及肥大。世界卫生组织(WHO)在关于哮喘病的免疫脱敏治疗中明确指导并指出:免疫脱敏治疗是根治过敏性疾病的唯一治疗方法。本文研究分析利用细胞因子中白细胞介素(IL-1、IL-2、IL-4、IL-5、IL-13、IL-33等)作为靶点进行靶向治疗支气管哮喘的临床应用及其进展。
Classic pathology physiological studies of bronchial asthma suggest that the main pathological changes caused by asthma mainly due to bronchial smooth muscle spasm and hypertrophy.In the treatment of asthma in the immune desensitization,world health organization（WHO） has clearly guided that immune desensitization therapy is the only cure for allergic diseases treatment.This paper analyzes cytokines interleukin（IL-1,IL-2,IL-4,IL-5,IL-13,IL-33,etc.） used as targeted,and its clinical application and progress in the treatment of bronchial asthma.
出处
《中国医药导报》
CAS
2011年第36期19-20,共2页
China Medical Herald
